PEGylated Mechano Growth Factor
Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
PEG-MGF is a PEGylated version of MGF (Mechano Growth Factor), where a polymer chain is attached to extend its duration. No peer-reviewed studies of PEG-MGF as a defined product exist. The PEG chain length, attachment site, and resulting properties are not standardised — meaning products sold under this name may differ from one another. It is one of the least-characterised compounds in this database.
No published studies found on PubMed.
PEG-MGF has no marketing authorisation. No peer-reviewed studies of PEG-MGF as a defined PEGylated peptide entity exist. The PEG chain length, attachment site, and resulting pharmacological properties are not standardised.
The absence of any characterisation studies means that products sold as PEG-MGF through unregulated channels have no defined molecular identity, no quality standards, and no basis for predicting their behaviour. This compound represents one of the least-characterised entries in this database.
Research suggests the same proposed mechanism as native MGF, with PEGylation extending the duration of action. However, no peer-reviewed studies of PEG-MGF as a specific, defined PEGylated peptide product have been published. Studies sometimes cited as PEG-MGF evidence actually used PEG-based hydrogel delivery systems for native MGF, which is a fundamentally different approach.
No peer-reviewed pharmacokinetic or pharmacodynamic data have been published for PEG-MGF. Studies sometimes cited as PEG-MGF evidence actually used different PEG-based delivery systems, not the same molecule. Additional PEGylation-specific concerns include anti-PEG antibody formation with repeated exposure (a documented phenomenon that can cause serious allergic reactions), altered tissue distribution, and potential PEG tissue accumulation. Products are essentially uncharacterised research chemicals. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Somatropin has been available since the mid-1980s and is one of the most established peptide therapies. It is sold under numerous brand names including Genotropin, Humatrope, Norditropin, and Omnitrope (the first biosimilar approved in the US, 2006). Approved indications include childhood and adult growth hormone deficiency, Turner syndrome, children born small for gestational age, Prader-Willi syndrome, idiopathic short stature, and short stature from chronic kidney disease. Daily injection has been the main burden of somatropin therapy, particularly for paediatric patients who may require years of treatment. This has driven the development of once-weekly alternatives (somatrogon and somapacitan), which are gradually changing the treatment landscape. Annual treatment costs remain substantial, and concerns about misuse in anti-ageing and performance enhancement contexts are ongoing.
Tesamorelin is marketed as Egrifta SV (approved November 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In clinical trials, it reduced visceral fat by approximately 15% compared to a 5% increase with placebo, and this reduction was sustained with continued treatment. Tesamorelin occupies a unique niche — it is the only approved GHRH analogue and the only medication specifically approved for HIV-associated lipodystrophy. Beyond its approved indication, it has attracted research interest for potential effects on liver fat, cognitive function, and peripheral neuropathy. Fat reduction reverses when treatment stops, and it is not approved for general weight loss or body composition purposes.
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes. Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
